The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina
Open accessAbstract
Objectives This study sought to examine the efficacy of ranolazine versus placebo on weekly angina frequency and sublingual nitroglycerin use in subjects with type 2 diabetes mellitus, coronary artery disease (CAD), and chronic stable angina who remain symptomatic despite treatment with up to 2 antianginal agents.Background Patients with diabetes have more extensive CAD than those without diabetes, and a high burden of angina. Ranolazine is not only effective in treating angina but also may improve glycemic control, thus providing several potential benefits in this high-risk group. We conducted a randomized trial to test the antianginal benefit of ranolazine in patients with diabetes and stable angina.Methods TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patients with diabetes, CAD, and stable angina treated with 1 to 2 antianginals. After a single-blind, 4-week placebo run-in, patients were randomized to 8 weeks of double-blind ranolazine (target dose 1000 mg bid) or placebo. Anginal episodes and nitroglycerin use were recorded with daily entry into a novel electronic diary. Primary outcome was the average weekly number of anginal episodes over the last 6 weeks of the study.Results A total of 949 patients were randomized across 104 centers in 14 countries. Mean age was 64 years, 61% were men, mean diabetes duration was 7.5 years, and mean baseline HbA1c was 7.3%. Electronic diary data capture was 98% in both groups. Weekly angina frequency was significantly lower with ranolazine versus placebo (3.8 [95% confidence interval (CI): 3.6 to 4.1] episodes vs. 4.3 [95% CI: 4.0 to 4.5] episodes, p = 0.008), as was the weekly sublingual nitroglycerin use (1.7 [95% CI: 1.6 to 1.9] doses vs. 2.1 [95% CI: 1.9 to 2.3] doses, p = 0.003). There was no difference in the incidence of serious adverse events between groups.Conclusions Among patients with diabetes and chronic angina despite treatment with up to 2 agents, ranolazine reduced angina and sublingual nitroglycerin use and was well tolerated. (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina [TERISA]; NCT01425359).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ranolazine reduces myocardial ischemia at the cellular level and is the only antianginal medication to be tested and found effective specifically in patients with T2DM.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
HEART DISEASE AND STROKE STATISTICS–2014 UPDATE: A REPORT FROM THE AMERICAN HEART ASSOCIATION
Tarver, T. (2014) · Journal of Consumer Health on the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,595
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationHeart disease and stroke statistics--2013 update: a report from the American Heart Association.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · eScholarship (California Digital Library) · Cited by 2,601
Self-citationPatient non-compliance with paper diaries
Stone, A. A., Shiffman, S., Schwartz, J. E., Broderick, J. E., & Hufford, M. R. (2002) · BMJ · doi:10.1136/bmj.324.7347.1193 · Cited by 810
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
CHAITMAN, B. R. (2004) · JAMA · doi:10.1001/jama.291.3.309 · Cited by 681
Self-citationElectrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties
Antzelevitch, C. N., Belardinelli, L., Zygmunt, A. C., Burashnikov, A., Diego, J. M. D., Fish, J. M., Cordeiro, J. M., & Thomas, G. (2004) · Circulation · doi:10.1161/01.cir.0000139333.83620.5d · Cited by 674
Self-citation
Cited by
Sorted by citations
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
2013 ESC guidelines on the management of stable coronary artery disease
Task Force Members, Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht296 · Cited by 4,510
Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 345
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Self-citationDevelopment and Validation of a Short Version of the Seattle Angina Questionnaire
Chan, P. S., Jones, P. G., Arnold, S. A., & Spertus, J. (2014) · Circulation. Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.000967 · Cited by 287
Self-citationTreatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 315
Coronary Microvascular Dysfunction
Schindler, T. H., & Dilsizian, V. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.11.036 · Cited by 224
Merz, C. N. B., Handberg, E. M., SHUFELT, C. L., Mehta, P. K., Minissian, M., Wei, J., Thomson, L., Berman, D. S., Shaw, L. J., Petersen, J. W., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv647 · Cited by 217
A 'diamond' approach to personalized treatment of angina
Ferrari, R., Camici, P. G., Crea, F., Danchin, N., Fox, K. M., Maggioni, A. P., Manolis, A. J., Marzilli, M., Rosano, G. M. C., & Lopez-Sendon, J. L. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.131 · Cited by 173
Treatment of refractory angina in patients not suitable for revascularization
Henry, T. D., Satran, D., & Jolicoeur, M. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.200 · Cited by 141
Ranolazine: A Contemporary Review
Rayner‐Hartley, E., & Sedlak, T. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003196 · Cited by 124
Wong, C. Y. J., Al‐Salami, H., & Dass, C. R. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13359 · Cited by 112
Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease
Reynolds, H. R., Picard, M. H., Spertus, J. A., Peteiro, J., Lopez-Sendon, J. L., Senior, R., El-Hajjar, M. C., Čelutkienė, J., Shapiro, M. D., Pellikka, P. A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046791 · Cited by 101
Self-citationEvidence in Guidelines for Treatment of Coronary Artery Disease
Jia, S., Liu, Y., & Yuan, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_2 · Cited by 102
Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial
Arnold, S. V., Kosiborod, M., Li, Y., Jones, P. G., Yue, P., Belardinelli, L., & Spertus, J. A. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000752 · Cited by 97
Self-citationConcomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 92
Mitochondrial dysfunction and its impact on diabetic heart
Verma, S. K., Garikipati, V. N. S., & Kishore, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.021 · Cited by 94
Ohman, E. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1502240 · Cited by 91
Belsey, J., Savelieva, I., Mugelli, A., & Camm, A. J. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314533217 · Cited by 84
Mansor, L. S., Fialho, M. D. L. S., Yea, G., Coumans, W. A., West, J. A., Kerr, M. J., Carr, C. A., Luiken, J. J. F. P., Glatz, J. F. C., Evans, R. D., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx045 · Cited by 80
Sequential proteome alterations during genesis and progression of colon cancer
Gustafsson, M., Bruch, H.-P., Franz�n, B., Ried, T., Bergmann, T., Auer, G., J�rnvall, H., Roblick, U. J., Hirschberg, D., Habermann, J. K., et al. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4049-4 · Cited by 75
Alexander, K. P., Weisz, G., Prather, K. O., James, S. K., Mark, D. B., Anstrom, K. J., Davidson-Ray, L. D., Witkowski, A., Mulkay, A. J., Osmukhina, A., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.019768 · Cited by 64
Self-citationMesnier, J., Ducrocq, G., Danchin, N., Ferrari, R., Ford, I., Tardif, J., Tendera, M., Fox, K. M., Steg, P. G., & for the CLARIFY Investigators (2021) · Circulation · doi:10.1161/circulationaha.121.054567 · Cited by 63
Antiarrhythmic properties of ranolazine: A review of the current evidence
Gupta, T., Khera, S., Kolte, D. S., Aronow, W. S., & Iwai, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.324 · Cited by 61
Pharmacological and emerging therapies in the treatment of chronic angina
Husted, S., & Ohman, E. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61283-1 · Cited by 60
Myocardial Metabolism in Diabetic Cardiomyopathy: Potential Therapeutic Targets
Sung, M. M. Y., Hamza, S. M., & Dyck, J. R. B. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6305 · Cited by 57
Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes
Eckel, R. H., Henry, R. R., Yue, P., Dhalla, A. K., Wong, P., Jochelson, P., Belardinelli, L., & Skyler, J. S. (2015) · Diabetes Care · doi:10.2337/dc14-2629 · Cited by 56
Self-citationTranscatheter treatment for refractory angina with the coronary sinus Reducer
Konigstein, M., Meyten, N., Verheye, S., Schwartz, M., & Banai, S. (2014) · EuroIntervention · doi:10.4244/eijv9i10a196 · Cited by 56
Metabolic abnormalities of the heart in type II diabetes
Amaral, N., & Okonko, D. O. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115580936 · Cited by 56
Shah, N. R., Cheezum, M. K., Veeranna, V., Horgan, S. J., Taqueti, V. R., Murthy, V. L., Foster, C. R., Hainer, J. M., Daniels, K. M., Rivero, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005027 · Cited by 51
Rambarat, C. A., Elgendy, I. Y., Handberg, E. M., Merz, C. N. B., Wei, J., Minissian, M., Nelson, M. D., Thomson, L., Berman, D. S., Shaw, L. J., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.081 · Cited by 51
Ranolazine for stable angina pectoris
Salazar, C. A., Basilio-Flores, J. E., Veramendi-Espinoza, L. E., Mejía-Dolores, J. W., Rodriguez, D. E. R., & Munarriz, C. A. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011747.pub2 · Cited by 50
Optimizing Management of Stable Angina
Montone, R. A., Rinaldi, R., Niccoli, G., Andò, G., Gragnano, F., Piccolo, R., Pelliccia, F., Moscarella, E., Zimarino, M., Fabris, E., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.015 · Cited by 50
Late sodium current associated cardiac electrophysiological and mechanical dysfunction
Yu, S., Li, G., Huang, C. L.-H., Lei, M., & Wu, L. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2079-7 · Cited by 52
Akasaka, T., Sueta, D., Tabata, N., Takashio, S., Yamamoto, E., Izumiya, Y., Tsujita, K., Kojima, S., Kaikita, K., Matsui, K., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004841 · Cited by 48
Medical treatment of stable angina: A tailored therapeutic approach
Manolis, A. J., Poulimenos, L. E., Ambrosio, G., Kallistratos, M. S., López-Sendón, J., Dechend, R., Mancia, G., & Camm, A. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.150 · Cited by 48
Management of Stable Angina – Current Guidelines: A Critical Appraisal
Thadani, U. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6681-2 · Cited by 47
Rousan, T. A., & Thadani, U. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.26.1 · Cited by 47
Management of Refractory Angina Pectoris
Cheng, K., Sainsbury, P. A., Fisher, M., & de Silva, R. (2016) · European Cardiology Review · doi:10.15420/ecr.2016:26:1 · Cited by 43
Drug Therapy for Stable Angina Pectoris
Rousan, T. A., Mathew, S. T., & Thadani, U. (2017) · Drugs · doi:10.1007/s40265-017-0691-7 · Cited by 46
Validation of the Seattle angina questionnaire in women with ischemic heart disease
Patel, K., Arnold, S. V., Chan, P. S., Tang, Y., Jones, P. G., Guo, J., Buchanan, D. M., Qintar, M., Decker, C., Morrow, D. A., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.04.012 · Cited by 39
Self-citationManagement of stable angina: A commentary on the European Society of Cardiology guidelines
Ambrosio, G., Mugelli, A., Lopez-Sendon, J. L., Tamargo, J. L., & Camm, A. J. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316648475 · Cited by 38
Bañón, D., Filion, K. B., Budlovsky, T., Franck, C., & Eisenberg, M. J. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.070 · Cited by 37
Alternative interventions for refractory angina
Sainsbury, P. A., Fisher, M., & de Silva, R. (2017) · Heart · doi:10.1136/heartjnl-2015-308564 · Cited by 34
Ueng, K., Chiang, C., Chao, T., Wu, Y., Lee, W.-L., Li, Y., Ting, K.-H., Su, C.-H., Lin, H., Su, T., et al. (2023) · PubMed Central · doi:10.6515/acs.202301_39(1).20221103a · Cited by 34
Self-citationValgimigli, M., & Biscaglia, S. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0422-4 · Cited by 33
Savarese, G., Rosano, G. M. C., D’Amore, C., Musella, F., Ratta, G. L. D., Pellegrino, A. M., Formisano, T., Vitagliano, A., Cirillo, A., Cice, G., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.131 · Cited by 32
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
Trimetazidine and Other Metabolic Modifiers
Guarini, G., Huqi, A., Cardiovascular Medicine Division, O. D. V., Morrone, D., Capozza, P., & Marzilli, M. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.15.2 · Cited by 29
Wanitschek, M. M., Dörler, J., & Alber, H. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605394 · Cited by 29
Management of Stable Angina in the Older Adult Population
Nanna, M. G., Wang, S. Y., & Damluji, A. A. (2023) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.122.012438 · Cited by 29
Ranolazine in Cardiac Arrhythmia
Saad, M. S., Mahmoud, A., Elgendy, I. Y., & Conti, C. R. (2015) · Clinical Cardiology · doi:10.1002/clc.22476 · Cited by 26
Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina
Banerjee, K., Ghosh, R. K., Kamatam, S., Banerjee, A., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.102 · Cited by 26
Antianginal Therapy for Stable Ischemic Heart Disease
Padala, S. K., Lavelle, M. P., Sidhu, M. S., Cabral, K. P., Morrone, D., Boden, W. E., & Toth, P. P. (2017) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248417698224 · Cited by 25
Role of ranolazine in heart failure: From cellular to clinic perspective
Kaplan, A., Amin, G., Abidi, E., Altara, R., Booz, G. W., & Zouein, F. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174787 · Cited by 23
Terruzzi, I. M., Anna, M., Pamela, S., Fernanda, V., Benedini, S., & Luzi, L. (2016) · Endocrine · doi:10.1007/s12020-016-1181-5 · Cited by 23
Ganesananthan, S., Rajkumar, C., Foley, M. J., Francis, D. P., & Al-Lamee, R. K. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac058 · Cited by 22
Update on ranolazine in the management of angina
Figueredo, V. M., Codolosa, J. N., & Acharjee, S. (2014) · Vascular Health and Risk Management · doi:10.2147/vhrm.s40477 · Cited by 21
Tamargo, J. L., & Lopez-Sendon, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2021-0058 · Cited by 21
Effects of Ranolazine on Quality of Life Among Patients With Diabetes Mellitus and Stable Angina
Arnold, S. V., Kosiborod, M., McGuire, D. K., Li, Y., Yue, P., Ben‐Yehuda, O., & Spertus, J. A. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2120 · Cited by 21
Self-citationDevelopmental actions of natriuretic peptides in the brain and skeleton
Waschek, J. A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4159-z · Cited by 21
Arnold, S. V., McGuire, D. K., Spertus, J. A., Li, Y., Yue, P., Ben-Yehuda, O., Belardinelli, L., Jones, P. G., Olmsted, A., Chaitman, B. R., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.06.020 · Cited by 19
Self-citationMourouzis, I. S., Mantzouratou, P., Galanopoulos, G. T., Kostakou, E., Dhalla, A. K., Belardinelli, L., & Pantos, C. I. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414524481 · Cited by 20
Self-citationResidual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus
Grodzinsky, A., Kosiborod, M., Tang, F., Jones, P. G., McGuire, D. K., Spertus, J. A., Beltrame, J. F., Jang, J.-S., Goyal, A., Butala, N. M., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.003553 · Cited by 20
Self-citationRanolazine: Multifaceted role beyond coronary artery disease, a recent perspective
Ghosh, G. C., Ghosh, R., Bandyopadhyay, D., Chatterjee, K., & Aneja, A. (2018) · Heart Views · doi:10.4103/heartviews.heartviews_18_18 · Cited by 20
Angina in 2022: Current Perspectives
Manfredi, R., Verdoia, M., Compagnucci, P., Barbarossa, A., Stronati, G., Casella, M., Russo, A. D., Guerra, F., & Ciliberti, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236891 · Cited by 22
Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes
Cassano, V., Tallarico, M., Armentaro, G., Sarro, C. D., Iannone, M., Leo, A., Russo, E., Citraro, R., Sarro, G. D., Hribal, M. L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416160 · Cited by 21
Montalescot, G., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Sechtem, U. P., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., Bugiardini, R., Crea, F., Cuisset, T., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.11.007 · Cited by 21
Quality of Life With Ivabradine in Patients With Angina Pectoris
Tendera, M., Chassany, O., Ferrari, R., Ford, I., Steg, P. G., Tardif, J., & Fox, K. M. (2015) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002091 · Cited by 19
Mehta, P. K., Sharma, S., Minissian, M., Harsch, M. R., Martinson, M., Nyman, J. A., Shaw, L. J., Merz, C. N. B., & WENGER, N. K. (2019) · Journal of Women s Health · doi:10.1089/jwh.2018.7019 · Cited by 19
Ielasi, A., Todaro, M. C., Grigis, G., & Tespili, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.018 · Cited by 18
Fanaroff, A. C., James, S. K., Weisz, G., Prather, K. O., Anstrom, K. J., Mark, D. B., Ben‐Yehuda, O., Alexander, K. P., Stone, G. W., & Ohman, E. M. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.056 · Cited by 18
Self-citationEmerging drugs for the treatment of angina pectoris
Chong, C., Ong, G. J., & Horowitz, J. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241231 · Cited by 17
Novel drugs for treating angina
Jones, D. A., Timmis, A., & Wragg, A. (2013) · BMJ · doi:10.1136/bmj.f4726 · Cited by 17
Dalal, J. J., & Mishra, S. (2017) · Indian Heart Journal · doi:10.1016/j.ihj.2017.04.001 · Cited by 17
State of the art approach to managing angina and ischemia: tailoring treatment to the evidence
Manolis, A. J., Boden, W. E., Collins, P., Dechend, R., Kallistratos, M. S., Sendon, J. L., Poulimenos, L. E., Ambrosio, G., & Rosano, G. M. C. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.003 · Cited by 17
Selvarajan, S. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10594.5448 · Cited by 16
Kohn, C. G., Parker, M. W., Limone, B. L., & Coleman, C. I. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.407 · Cited by 17
The risk of cardiovascular side effects with anti-anginal drugs
Rousan, T. A., Mathew, S. T., & Thadani, U. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1238457 · Cited by 16
Pettus, J., McNabb, B., Eckel, R. H., Skyler, J. S., Dhalla, A. K., Guan, S., Jochelson, P., Belardinelli, L., & Henry, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12629 · Cited by 17
Self-citationPharmacological approaches of refractory angina
Giannopoulos, A. A., Giannoglou, G. D., & Chatzizisis, Y. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.008 · Cited by 16
Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant
ZAIDI, S. A., Shaikh, D. H., Saad, M., & Vittorio, T. J. (2019) · Case Reports in Medicine · doi:10.1155/2019/2740617 · Cited by 15
Nowbar, A. N., Rajkumar, C., Foley, M., Ahmed-Jushuf, F., Howard, J. H., Seligman, H., Petraco, R., Sen, S., Nijjer, S. S., Shun-Shin, M. J., et al. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00649 · Cited by 15
Souza, D. S., Marques, L. P., Costa, A., Cruz, J. S., Rhana, P., Santos‐Miranda, A., Joviano‐Santos, J. V., Durço, A. O., de Vasconcelos, C. M. L., & Roman‐Campos, D. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120945 · Cited by 14
Efficacy and Safety of Ranolazine in Patients With Chronic Stable Angina
Kloner, R. A., Hines, M. E., & Geunes-Boyer, S. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.11.2711 · Cited by 14
Impact of angina frequency on health utility values of patients with chronic stable angina
Kohn, C. G., Parker, M. W., Limone, B. L., & Coleman, C. I. (2014) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-12-39 · Cited by 14
Coronary artery disease in the military patient
Parsons, I., White, S., Gill, R., Gray, H., & Rees, P. S. C. (2015) · Journal of the Royal Army Medical Corps · doi:10.1136/jramc-2015-000495 · Cited by 14
Tawfik, M. K., & Ameen, A. M. (2019) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0571 · Cited by 14
Guarini, G., Huqi, A., Morrone, D., & Marzilli, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6677-y · Cited by 13
Efficacy and Safety of Ranolazine in Diabetic Patients: A Systematic Review and Meta-analysis
Zeng, X., Zhang, Y., Lin, J.-H., Zheng, H., Peng, J., & Huang, W. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017747901 · Cited by 14
Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine
Rosano, G. M. C., Vitale, C., & Volterrani, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6674-1 · Cited by 13
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Михайловна, Г. Е., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-3-6-76 · Cited by 12
Mansouri, M. H., Mansouri, P., Sadeghi, M., Hashemi, S. M., Khosravi, A., Behjati, M., Shahabi, J., Mansouri, A., Zavar, R., Amirpour, A., et al. (2023) · Clinical Cardiology · doi:10.1002/clc.24158 · Cited by 12
Hidalgo‐Vega, Á., Ramos-Goñi, J. M., & Villoro, R. (2013) · The European Journal of Health Economics · doi:10.1007/s10198-013-0534-8 · Cited by 12
Coleman, C. I., Freemantle, N., & Kohn, C. G. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008861 · Cited by 12
Page, R. L., II, Ghushchyan, V. H., Read, R. A., Hartsfield, C. L., Koch, B., & Nair, K. V. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.002 · Cited by 11
Management of Angina Post Percutaneous Coronary Intervention
Rodriguez, J. B. C., & Kar, S. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-1259-9 · Cited by 11
Ranolazine Refractory Angina Registry
Bennett, N. M., Iyer, V., Arndt, T. L., Garberich, R., Traverse, J. H., Johnson, R. K., Poulose, A. K., Lips, A., Morgan, J. M., & Henry, T. D. (2014) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000022 · Cited by 11
Zweiker, R., Aichinger, J., Metzler, B., Lang, I. M., Wallner, E. M., & Delle‐Karth, G. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1481-x · Cited by 11
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.03.012 · Cited by 10
Metadata
- Authors
- Kosiborod, M., Arnold, S. V., Spertus, J. A., McGuire, D. K., Li, Y., Yue, P., Ben-Yehuda, O., Katz, A., Jones, P. G., Olmsted, A., Belardinelli, L., & Chaitman, B. R.
- Affiliations
- Saint Luke's Health System (US)
- University of Missouri–Kansas City (US)
- The University of Texas Southwestern Medical Center (US)
- Gilead Sciences (United States) (US)
- Ben-Gurion University of the Negev (IL)
- Saint Louis University (US)
- Corresponding author
- Kosiborod, Mikhail
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 61
- Issue
- 20
- Pages
- 2038-2045
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W126353551
- Cited by
- 205
- References
- 37
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 11 · 2020: 8 · 2019: 15 · 2018: 11 · 2017: 20 · 2016: 28 · 2015: 30 · 2014: 28 · 2013: 17
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gilead Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ranolazine, type 2 diabetes, stable angina, coronary artery disease, angina frequency, antianginal therapy, electronic diary, glycemic control, adverse events, serious adverse events, antiplatelet therapy, antianginal drugs, HbA1c
- MeSH terms
- Ranolazine, Acetanilides, Aged, Coronary Artery Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Enzyme Inhibitors, Female, Nitroglycerin, Glycated Hemoglobin, Humans, Male, Middle Aged, Piperazines, Vasodilator Agents, Treatment Outcome, Sodium Channel Blockers, Angina, Stable
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
